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1. INTRODUCTION
1.1MICROALBUMINURIA
Microalbuminuria  has  been defined  as  albumin  excretion  of  20  to  200 mcg / 
minute or 30 to 300 mg /24 hour in a 24 hour urinary sample. Anything above this level 
is called macroalbuminuria.
Microalbuminuria  can  also  be  defined  in  terms  of  the  urinary  albumin  –to  –
creatinine ratio (UACR). A ratio greater than 30 mg /g in the first voided sample in the 
morning (clean, midstream) is considered abnormal.
TABLE-1.1 Urine assays for Albuminuria/Proteinuria
24-Hour Albumin (mg/24 h)
Albumin/Creatinine
Ratio(mg/g)
Dipstick Proteinuria
24-Hour  Urine  Protein  (mg/24h)
Normal
8-10
<30
-
<150
Microalbuminuria
30-300
30-300
-/Trace/1+
-
Proteinuria
>300
>300
Trace-3+
>150
Albuminuria detected by immunoturbidometric assay
Albumin represents 30–70% of the total protein excreted in the urine 
A
Microalbuminuria - the finding of albumin in the urine not detectable by the 
urine  dipstick  precedes  the  decline  in  GFR  and  heralds  renal  and  cardiovascular 
complications.
 If  the  patient  already  has  established  proteinuria,  then  testing  for 
microalbumin  is  not  necessary.  Antihypertensive  treatment  reduces  albuminuria  and 
retards its progression even in normotensive diabetic patients.
         The prevalence of microalbuminuria in essential hypertension has been 
variably studied and quoted as between 10 and 40%. Many studies have shown positive 
association  of  microalbuminuria  in  essential  hypertensive  patients  with  severity  of 
hypertension, particularly with systolic blood pressure and pulse pressure. While some 
studies show it correlates more with mean ambulatory pressure.
           In people older than 45 years with stage II hypertension, microalbuminuria 
seems to be strongly associated with severe cardiovascular risk factors and target organ 
damage.
Microalbuminuria strongly predicts cardiovascular morbidity and mortality, 
clinical nephropathy and progression of renal disease in high risk population.
Microalbuminuria  has  been  shown  to  be  an  independent  risk  factor  for 
cardiovascular diseases in hypertensive patients.  Several retrospective and 
cross  sectional  studies  reported  that  the  prevalence  of  cardiovascular 
disease is significantly higher among hypertension with microalbuminuria than patients 
without microalbuminuria.
Most of the studies show that microalbuminuria in hypertension is not affected by 
age, body weight, smoking, alcohol or family history of hypertension.
Microalbuminuria has been proposed as a marker of generalized vascular disease 
with arterial endothelial dysfunction involved in the pathogenesis of atherothrombotic 
vascular disease.
Hypertension doubles the risk of cardiovascular diseases, including coronary heart 
disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, renal 
failure, and peripheral arterial disease.
 In this background, cross sectional  study of 60 patients  with hypertension of 
various  age  categories  and  duration  of  hypertension  were  studied.  Prevalence  of 
microalbuminuria and its correlation with duration and severity of hypertension (target 
organ damage) were studied in South Indian patients, especially in southern districts of 
Tamilnadu, who are attending the Government Rajaji Hospital, Madurai. The study was 
undertaken in the department of medicine, Government Rajaji Hospital, Madurai.
u
It is hoped that this study may help to prevent the dreaded complications of 
untreated  hypertension  in  our  own  South  Indian  population,  by  early  detection  of 
microalbuminuria. 
The study also stresses the importance of regular intake of anti hypertensive 
drugs and thereby preventing early morbidity and mortality. 
Review of literature
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2. Review of literature
2.1 DEFINITION
TABLE 2.1.STAGING HYPERTENSION-JNC 7
Blood Pressure (BP) Stage Systolic BP (mm Hg) Diastolic BP (mm Hg)
Normal <120 <80
Prehypertension 120-139 80-89
Stage 1 hypertension 140-159 90-99
Stage 2 hypertension ≥160 ≥100
Clinically, hypertension might  be  defined  as  that  level  of  blood pressure  at  
which  the  institution  of  therapy  reduces  blood  pressure–related  morbidity  and 
mortality.
Calculation of seated BP is based on the mean of two or more readings on two 
separate office visits.
According to JNC (Joint National Committee) 7 report, in adults aged 18 years 
and above, systolic blood pressure of <120 mm of Hg and diastolic blood pressure of 
<80mm of Hg is normal. Systolic blood pressure of 120 – 139 mm of Hg and diastolic 
blood pressure of 80 – 89 mm of Hg is prehypertension.
b
In stage 1 hypertension, the systolic blood pressure is140-159 mm Hg and 
diastolic blood pressure is  90-99 mm of Hg. In stage 2 hypertension, systolic blood 
pressure is ≥ 160 mm of Hg and diastolic blood pressure is ≥ 100 mm of Hg.
The prevalence of hypertension in India varies widely from 3.80 to 15.63% 
in men and 2 to 15.38% women in the urban areas and from 1.57 to 6.93% in men and 
2.38% to 8.81% in women in rural areas. 
Hypertension is a major risk factor for myocardial ischaemia and infarction. 
Patients with hypertension are also more susceptible to silent ischaemia.  Endothelial 
cell is probably both a victim and an active participant in the vascular changes, that leads 
to  hypertension.  Microalbuminuria  reflects  widespread  vascular  damage  due  to 
generalized endothelial dysfunction that initiates the atherosclerotic process.
Microalbuminuria  has  been  proposed  as  a  marker  of  endothelial 
dysfunction,  as  microalbuminuria  has  been  related  to  elevated  concentrations  of 
accepted  markers  of  endothelial  dysfunction  such  a  Von  Willebrand  factor, 
thrombomodulin and activated factor VII.
Microalbuminuria might lead to hemodynamic strain and instability which can then, 
start the atherosclerotic process and eventually leads 
to cardiovascular events such as congestive heart failure, acute coronary syndromes, 
myocardial infarction and stroke. 
2.2 HOME AND AMBULATORY MONITORING
Ambulatory monitoring provides automated measurements of BP over a 24-
hour  period,  while  patients  are  engaging  in  their  usual  activities,  including  sleep. 
Prospective  outcome studies  in  both  treated  and  untreated  patients  have  shown that 
ambulatory  BP  measurement  predicts  fatal  and  nonfatal  myocardial  infarction  and 
stroke, better than standard office measurements.  Recommended normal values include 
an average daytime BP below 135/85 mm Hg, night time BP below 120/70 mm Hg, and 
24-hour BP below 130/80 mm Hg. Some experts have recommended a lower cutoff 
value of 130/80 mm Hg as a more stringent definition of normal daytime BP.
2.3 PATHOPHYSIOLOGY OF MICROALBUMINURIA 
2.3.1 Glomerular and tubular mechanisms 
  The intimate relationship between low level albumin excretion and vascular 
permeability makes urinary albumin excretion, highly sensitive to the presence of any 
inflammatory process, including cardiovascular disease. The kidney is ideally placed to 
amplify any small changes in systemic vascular permeability. 
a
The glomeruli receive 25% of the cardiac output. Of the 70kg of albumin 
that pass through the kidneys every 24 hour, less than 0.01% reaches the glomerular 
ultrafiltrate (i.e, less than 7g / 24hour) and hence enters the renal tubules.
 Almost all filtered albumin is reabsorbed by the proximal tubule via a high 
– affinity,  low – capacity  endocytotic  mechanism,  with only 10 – 30 mg /  24 hour 
appearing in the urine. Assuming that, 7g of albumin is filtered every 24 hour, a 1% 
increase  in  systemic  vascular  permeability  in  response  to  an  inflammatory  stimulus 
would  result  in  an  additional  70mg  of  albumin  into  the  filtrate.  Since  tubular 
mechanisms  for  albumin  reabsorption  are  near  saturation,  urinary  albumin  excretion 
would increase from a maximum of 30 to approximately 100mg / 24hour. 
 Glomerular  permeability  to  albumin  is  dependent  on  endothelial  charge 
selectivity as well as size selectivity. The negative charge conferred on the glomerular 
membrane by its constituent glycoproteins plays a role in restricting the permeability of 
glomerular charge selectivity, and this is found in diabetic and non diabetic populations 
with microalbuminuria.
2.3.2 Protiens in normal urine
Charge and size selectivity normally prevent virtually all plasma albumin, 
globulins and other large molecular weight proteins from crossing the 
glomerular wall. However, if this barrier is disrupted, there can be leakage 
of plasma proteins into the urine. Smaller proteins <20 kda are freely filtered but are 
readily reabsorbed by the proximal tubule.
 Normal individuals excrete <150 mg/d of total protein and <30 mg/d of 
albumin. The remainder of the protein in the urine is secreted by the tubules, (Tamm-
Horsfall,  IgA,  and urokinase)  represents  small  amounts  of  filtered β2-microglobulin, 
apoproteins, enzymes and peptide hormones.
In  addition  to  treatment  of  hypertension  in  general,  the  use  of  ACE 
inhibitors and ARBs in particular are associated with additional renoprotection. These 
salutary  effects  are  mediated  by  reducing intraglomerular  pressure  and inhibition  of 
angiotensin driven sclerosing pathways, in part through inhibition of TGF-β mediated 
pathways.
 Hypertension  more  commonly  accompanies  microalbuminuria or 
macroalbuminuria in type 2 DM.
2.4 Blood pressure and microalbuminuria 
Similarly, alterations in the fraction of plasma filtered by the glomerulus 
due to  changes  in  blood pressure  and intraglomerular  pressure  regulation,  may  also 
result  in  relatively  large  changes  in  urinary  albumin  excretion.  It  is  therefore  not 
surprising,  that  several  studies  have  shown  a  positive  correlation  between 
microalbuminuria and blood pressure, especially at 
pressures < 150/90mmHg. (Pontrmoli  R,  Sofia  A, Tirotta A, Revera M, 
Nicotella C, Viazzi F et.al., Deckert T,  Kofoed – Enevoldsen A, Videl P, Norgaard K, 
Andreasen HB, Feldt – Rasmussen B). 
In  addition,  insertion  polymorphism  of  the  angiotensin  –  1  converting 
enzyme (ACE) gene, leading to higher circulating activities of ACE and a predisposition 
to  cardiovascular  disease,  has  been  shown  to  be  associated  with  microuminuria  as 
measured  by  the  albumin  /  creatinine  ratio  (Kofoed  –  Enevoldsen  A,  Foyle  WJ, 
Fernandez  M,  Ydkin  JS.).ACE  activates  angiotensin  II  as  part  of  the  rennin  – 
angiotensin  –  aldosterone  axis  regulating  blood  pressure,  angiotensin  II  having   a 
powerful vasoconstrictor action as well as stimulating aldosterone release. 
Systemic blood pressure on the other hand, correlated with intraglomerular 
pressure and microalbuminuria (Rodicio J, Campo C, Ruilope L., Lydakis C, Lip GY). 
Moreover,  systolic  blood  pressure  is  one  of  the  most  relevant  determinants  of 
microalbuminuria (Bianchi S, Bigazzi R, Campese VM). However, microalbuminuria 
continues  to  be  an  independent  risk  factor  for  cardiovascular  diseases  even  after 
adjustment for blood pressure.
In  hypertensive  patients,  microalbuminuria  is  related  to  salt  sensitivity, 
absence of a nocturnal dip in blood pressure and higher mean 24 hour blood pressure 
measurements. All of these factors have been related to a 
high  prevalence  of  cardiovascular  disease  in  hypertensive  population 
(Lydakis C, Lip GY., Morimoto A, Uzu T, Fujii T, et.al).
2.5 Factors that cluster with microalbuminuria
 Microalbuminuria  may  be  related  to  target  organ  damage  by  several  biological  
pathways:
Insulin resistance 
Central obesity
Low levels of high – density lipoprotein cholesterol
High triglyceride levels 
Systolic hypertension 
Lack of nocturnal dip in blood pressure on 24  hour monitoring 
Salt sensitivity
Endothelial dysfunction 
Hypercoagulability
Impaired fibrinolysis
Renal dysfunction
2.6 Endothelial function 
Over 20 years ago, Parving (Parving HH, Jensen M, Morgensen CE, Evrin 
PE.) showed that urinary albumin excretion correlated with blood 
pressure and the transcapillary escape rate of radiolabelled albumin in patients 
with essential hypertension.
 Increased  systemic  capillary  permeability  has  also  been  linked  with 
microalbumin in health, (Felt – Rasmussen B) and recent studies suggest that endothelial 
dysfunction  may  lead  to  impaired  insulin  action  as  well  as  to  capillary  leakage  of 
albumin,  features which may be linked to a  predisposition to cardiovascular  disease 
(Yudkin JS) .
2.7 Clinical features
In uncomplicated hypertensive patients, it is almost always asymptomatic. 
A person may be unaware of the consequent progressive target organ damage for as long 
as 10 to 20 years.  Symptoms often attributed to hypertension are headache,  tinnitus, 
dizziness and fainting which may be observed as commonly as in the normotensive 
population. 
2.8 Complications of hypertension 
The  higher  the  level  of  blood  pressure,  the  more  likely  that  various 
cardiovascular  diseases  will  develop  prematurely  through  acceleration  of 
atherosclerosis,  the  pathological  hallmark  of  uncontrolled  hypertension.  If  untreated 
about 50% of hypertensive people die of coronary artery disease or congestive heart 
failure, about 33% of stroke, and 10 to 15% of renal failure. 
f
Those with rapidly accelerating hypertension die more frequently of renal 
failure, as do those who are diabetic, once proteinuria or other evidence of nephropathy 
develops. Death is usually attributed to stroke or myocardial infarction, instead of to the 
hypertension that was largely responsible.
In general, the vascular complications of hypertension can be considered as 
either  “hypertensive”  or  “atherosclerotic”.  The  former  are  more  directly  caused  by 
increased blood pressure per se and can be prevented by lowering this level; the latter 
have more multiple causations. 
s. no Hypertension Atherosclerotic
1.
2.
3.
4. 
5.
Accelerated – malignant phase
Hemorrhagic stroke 
Congestive heart failure
Nephrosclerosis  
Aortic dissection 
Coronary heart disease
Sudden death
 Arrhythmias
Atherothrombotic stroke 
Peripheral vascular disease
TABLE 2.2 Vascular complications of hypertension 
2.9 HEART-HYPERTENSION-MICROALBUMINURIA
Heart disease is the most common cause of death in hypertensive patients. Hypertensive 
heart disease is the result of structural and functional adaptations, leading to left 
ventricular hypertrophy, diastolic dysfunction, CHF, 
abnormalities of blood flow due to atherosclerotic coronary artery disease and 
microvascular disease, and cardiac arrhythmias. 
Both genetic and hemodynamic factors contribute to left ventricular hypertrophy. 
Clinically, left ventricular hypertrophy can be diagnosed by electrocardiogram, although 
echocardiography provides a more sensitive measure of left ventricular wall thickness. 
Individuals with left ventricular hypertrophy are at increased risk for CHD, stroke, CHF, 
and sudden death. Aggressive control of hypertension can regress or reverse left 
ventricular hypertrophy and reduce the risk of cardiovascular disease.
It has been acknowledged that microalbuminuria is a new marker of cardiologist. 
Nephrologists and diabetologists have traditionally measured microalbuminuria in their 
patients to monitor the development and progression of kidney disease, but now studies 
such as HOPE trial have shown a clear relationship between microalbuminuria and 
cardiovascular events.
In the MONICA study, one of the largest longitudinal studies to investigate predictive 
role of microalbuminuria, hypertensive subjects with albuminuria showed a four-fold 
raised risk of ischaemic heart diseases compared with hypertensive subjects without 
albuminuria.
a
2.10 BRAIN-HYPERTENSION- MICROALBUMINURIA
Hypertension is an important risk factor for brain infarction and hemorrhage. 
Approximately 85% of strokes are due to infarction and the remainder is due to 
hemorrhage, either intracerebral hemorrhage or subarachnoid hemorrhage. The 
incidence of stroke rises progressively with increasing blood pressure levels, particularly 
systolic blood pressure in individuals >65 years. Treatment of hypertension 
convincingly decreases the incidence of both ischemic and hemorrhagic strokes. 
Hypertension is also associated with impaired cognition in an aging population, and 
longitudinal studies support an association between mid-life hypertension and late-life 
cognitive decline. Hypertension-related cognitive impairment and dementia may be a 
consequence of a single infarct due to occlusion of a "strategic" larger vessel or multiple 
lacunar infarcts due to occlusive small vessel disease resulting in subcortical white 
matter ischemia. 
Several clinical trials suggest that antihypertensive therapy has a beneficial effect on 
cognitive function, although this remains an active area of investigation. 
Cerebral blood flow remains unchanged over a wide range of arterial pressures (mean 
arterial pressure of 50–150 mmHg) through a process termed auto regulation of blood 
flow. In patients with the clinical syndrome of 
malignant hypertension, encephalopathy is related to failure of autoregulation of 
cerebral blood flow at the upper pressure limit, resulting in vasodilation and 
hyperperfusion. Signs and symptoms of hypertensive encephalopathy may include 
severe headache, nausea and vomiting (often of a projectile nature), focal neurologic 
signs, and alterations in mental status. Untreated, hypertensive encephalopathy may 
progress to stupor, coma, seizures, and death within hours. 
                   It has been shown that hypertensive patients with microalbuminuria have an 
increased thickness of the carotid intima and media layers suggesting a greater degree of 
atherosclerosis.
2.11 RENAL VASCULAR INJURY -MICROALBUMINURIA
Whether it is "essential" or of known etiology, hypertension results in development of 
intrinsic lesions of the renal arterioles (hyaline arteriolosclerosis) that eventually lead to 
loss of function (nephrosclerosis). 
Arteriolar nephrosclerosis is seen in patients who are hypertensive (BP > 150/90 mmHg) 
for an extended period of time but whose hypertension has not progressed to a malignant 
form. Such patients, usually in the older age group, are often discovered to be 
hypertensive on routine physical examination or as a result of nonspecific 
symptomatology (e.g., headaches, weakness, and palpitations).
s
The characteristic pathology is in the afferent arterioles, which have thickened walls due 
to deposition of homogeneous eosinophilic material (hyaline 
arteriolosclerosis).Narrowing of vascular lumen leads to ischemic injury to glomeruli 
and tubules.
     Physical examination may reveal changes in retinal vessels (arteriolar 
narrowing Sand/or flame-shaped hemorrhages), cardiac hypertrophy, and possibly signs 
of congestive heart failure. Renal disease may manifest as a mild to moderate elevation 
of serum creatinine concentration, microalbuminiria, or proteinuria.
2.12 ROLE OF RAAS
The Renin angiotensin aldosterone system plays an important role in modulating the 
effects of microalbuminuria.
Angiotensinogen II activates AT 1 receptor resulting in the stimulation of oxidative 
stress, inflammatory mediators, proliferation, and other mechanisms that contribute to 
the progression of renal disease. It is clear that blockade of RAS results in decreased 
progression of renal disease.
A critical driving factor with both renal and wider cardiovascular pathologies is over 
activation of RAS. Agents that delay the progression of renal disease therefore are also 
likely to be cardio protective. These agents not only lessen the systemic consequences of 
renal dysfunction, but may have 
cardio protective effects by exerting beneficial on endothelia elsewhere in the body and 
within the heart. 
Renal artery stenosis
Renal artery stenosis (RAS) is the partial or complete occlusion of the renal 
artery, resulting in ischemia to kidney and renovascular hypertension.
RAS should be considered in the setting of poorly controlled hypertension 
despite four or more medications, hypertension with asymmetric kidney sizes, flash 
pulmonary edema, acute renal failure upon initiation of ACE inhibitors or ARBs or the 
presence of abdominal bruit.
A stenosis greater than 70%is considered potentially significant. Diagnosis may be 
obtained by a Doppler ultrasound.
Normal kidney sizes and textures on renal ultrasound and lack of 
protienuria reflect normal underlying renal parenchyma and a higher likelihood of renal 
function improving with revascularization.
Unilateral renal artery stenosis alone rarely results in  significant decline in 
GFR, so the treatment goals are more focused on controlling hypertension with ACE 
inhibitors or ARBs.
Bilateral renal artery stenosis angioplasty with stenting and bypass is the 
treatment of choice.  
t
2.13 PERIPHERAL VASCULAR DISEASE-HYPERTENSION
In addition to contributing to the pathogenesis of hypertension, blood vessels may be a 
target organ for atherosclerotic disease secondary to long-standing elevated blood 
pressure. Hypertensive patients with arterial disease of the lower extremities are at 
increased risk for future cardiovascular disease. 
Although patients with stenotic lesions of the lower extremities may be asymptomatic, 
intermittent claudication is the classic symptom of PAD. This is characterized by aching 
pain in the calves or buttocks while walking that is relieved by rest.
 The ankle-brachial index is a useful approach for evaluating PAD and is defined 
as the ratio of noninvasively assessed ankle to brachial (arm) systolic blood pressure.
An ankle-brachial index < 0.90 is considered diagnostic of PAD and is associated with 
>50% stenosis in at least one major lower limb vessel. Several studies suggest that an 
ankle-brachial index < 0.80 is associated with elevated blood pressure, particularly 
systolic blood pressure.
s
FUNDUS PICTURE OF HYPERTENSIVE RETINOPATHY
(Arteriloar attenuation, cotton wool spots, flame shaped hemorrhages)
HYPERTENSION-RETINOPATHY
Grade 
1
Thickening  and  tortuosity  of  arteries  showing  ‘silver  wiring’ 
appearance
Grade 
2 Grade I changes plus arteriovenous nipping
Grade 
3
Grade II changes plus flame-shaped (superficial) haemorrhages and 
cotton wool exudates
Grade 
4 Grade 3 changes plus papilloedema
TABLE 2.3 Keith and Wagner's grading of hypertensive retinopathy
 
Marked systemic hypertension causes sclerosis of retinal arterioles, splinter 
hemorrhages, focal infarcts of the nerve fiber layer (cotton-wool spots), and leakage of 
lipid and fluid (hard exudate) into the macula. 
In hypertensive crisis, sudden visual loss can result from vasospasm of retinal arterioles 
and retinal ischemia. In addition, acute hypertension may produce visual loss from 
ischemic swelling of the optic disc. 
Patients with acute hypertensive retinopathy should be treated by lowering the blood 
pressure. However, the blood pressure should not be reduced 
precipitously, because there is a danger of optic disc infarction from sudden 
hypoperfusion.
Secondary Causes of Systolic and Diastolic Hypertension
Renal
  Parenchymal diseases,
  Renal cysts (including polycystic kidney disease),
  Renal tumors (including renin-secreting tumors),
  Obstructive uropathy
  
  Arteriosclerotic,
  Fibromuscular dysplasia
Adrenal
  Primary aldosteronism,
  Cushing's syndrome,
  17-hydroxylase deficiency, 
  11-hydroxylase deficiency, 
  11-hydroxysteroid dehydrogenase deficiency    (licorice), pheochromocytoma
Aortic coarctation
Obstructive sleep apnea
Preeclampsia/eclampsia
Neurogenic
  Psychogenic, diencephalic syndrome, 
  Familial dysautonomia, 
  Polyneuritis (acute porphyria, lead poisoning), 
  Acute increased intracranial pressure, 
  Acute spinal cord section
Miscellaneous endocrine
  Hypothyroidism, 
  Hyperthyroidism,
  Hypercalcemia,
  Acromegaly
Medications
  High-dose estrogens, adrenal steroids,    decongestants, appetite suppressants,
  Cyclosporine, tricyclic antidepressants, 
monamine oxidase inhibitors, 
  Erythropoietin, 
  Nonsteroidal anti-inflammatory agents, cocaine
 
Mendelian forms of hypertension
2.14. Guidelines for measuring blood pressure
a. Posture
1.  Sitting postures are usually  adequate  for  routine follow – up.  Patient 
should sit quietly with back supported for five minutes and arm supported at the 
level of heart. 
2. For patients who are over 65, diabetic or receiving anti hypertensive therapy, check 
for postural changes by taking readings immediately and 2 minutes after the patient 
stands.
b. Circumstances 
No caffeine for preceding hour. 
No smoking for preceding 15 minutes. 
No exogenous adrenergic stimulants like phenylephrine in nasal decongestants or eye 
drops for pupillary dilation. 
A quite, warm setting.
Home readings taken under various circumstances 24 hour ambulatory recordings may 
be preferable. 
 
 
C. EQUIPMENT
C. Cuff Size
The bladder should encircle and cover 2/3 of arm length. 
If not place the bladder over the brachial artery, if bladder is too small, spuriously 
high readings may result. 
d. Manometer
Aneroid gauges should be caliberated every six months against the mercury manometer. 
For infants, use ultrasound equipment. e.g. The Doppler method.
e. Technique
i. Number of readings
On each occasion, take atleast two readings, separated by as much time as practical. If 
reading varies by more than 5 mm Hg, take additional readings until two are close. 
For diagnosis, obtain atleast three sets of readings a week apart. 
F
Initially, take pressure in both arms, if pressure differs, use arm with higher pressure. 
If arm pressure is elevated, take pressure in one leg, particularly in patients below age 
30.
ii. Performance
Inflate the bladder quickly to a pressure 20 mm Hg above the systolic, as recognized by 
disappearance of the radial pulse.
Deflate the bladder 3 mm Hg every second.
Record the Korotkoff phase V(disappearance) except in children,in whom use of phase 
IV (muffling) is advocated.
If korotkoff sounds are weak, have the patients raise the arm, open and close the hand 5 
to 10 times, after which the bladder should be inflated quickly.
  f. Recording
          Note the blood pressure, patient’s position, and the arm, cuff size (eg.140/90, 
seated, right arm, and large adult cuff) 
2.15 SCREENING FOR MICROALBUMINURIA
ADA-American  Diabetes  Association  recommended  methods  for  measuring 
microalbuminuria
m
Albumin to creatinine ratio in a random spot collection
24- hour collection with creatinine
Timed urine  collection over four hours or overnight
ADA advises that the first method is often easy to carry out in the office setting and 
generally provides accurate information.The first void urine or other morning collections 
are best because of diurnal variations in albumin secretion.
2.16 Interventions to reduce microalbuminuria
Endothelial dysfunction occurs early in patients with microalbuminuria. Several large 
studies show modulating microalbuminuria has beneficial effects.
Non pharmacological measures
These include weight loss, exercise and eating a low fat diet, most of the time these is 
however not enough.
Pharmacological agents 
 Statins, ACE inhibitors, ARBs have been shown in several land mark 
studies to decrease high blood pressure and microalbuminuria. 
Either ACE inhibitors or ARBs should be used to reduce the progression from 
microalbuminuria to macroalbuminuria and the associated 
decline in GFR that accompanies macroalbuminuria in individuals with “Hypertension”. 
Although direct comparisons of ACE inhibitors and ARBs are lacking, most experts 
believe that the two classes of drugs are equivalent. ARBs can be used as an alternative 
in patients who develop ACE inhibitor –associated cough or angioedema. 
After 2–3 months of therapy in patients with microalbuminuria, the drug dose is 
increased until either the microalbuminuria disappears or the maximum dose is reached. 
If use of either ACE inhibitors or ARBs is not possible, then calcium channel blockers 
(non-dihydropyridine class), beta blockers, or diuretics should be used. However, their 
efficacy in slowing the fall in the GFR is not proven. Blood pressure control with any 
agent is extremely important, but a drug-specific benefit in nephropathy, independent of 
blood pressure control, has been shown only for ACE inhibitors and ARBs in patients 
with DM.
The ADA suggests modest restriction of protein intake in diabetic individuals with 
microalbuminuria (0.8 g/kg per day) or macroalbuminuria (<0.8 g/kg per day, which is 
the adult Recommended Daily Allowance, or ~10% of the daily caloric intake).
t
Nephrology consultation should be considered when the estimated GFR < 60 mL/min 
per 1.743 m2. Once macroalbuminuria ensues, the likelihood of ESRD is very high.
 
Aims and objectives
AIMS AND OBJECTIVES OF THE STUDY
To study the prevalence of microalbuminuria in patients with hypertension.
To study whether microalbuminuria correlates with duration of hypertension.
To study whether microalbuminuria correlates with severity of hypertension-JNC 7 
staging.
To study whether microalbuminuria correlates with severity of Target organ damage 
(TOD).
Materials and methods
MATERIALS AND METHODS
SETTING
Outpatient clinic of Government Rajaji Hospital, Madurai.
DESIGN OF STUDY
Analytical-cross sectional study
PERIOD OF STUDY
Six months (August 2008-January 2009)
SAMPLE SIZE AND SELECTION OF STUDY SUBJECTS
Sixty hypertensive patients (both newly and previously diagnosed) attending the 
outpatient clinic were included in this Analytical-cross sectional study. This study group 
included 33 males and 27 females. The subjects included in the age groups ranging 
between 20yrs and 70yrs.
DETAILS OF STUDY SUBJECTS
Blood pressure was recorded using sphygmomanometer with standard cuff on 2 
occasions 10 minutes apart. Patients should have refrained 
from smoking or drinking tea or coffee for at least 30 minutes before measuring BP .The 
higher of the two readings was taken as the patient’s blood pressure.
Patients’ height and weight were measured and the body mass index was 
calculated using the formula weight/height2. All the peripheral pulses were checked with 
special attention to carotids and femorals, to detect evidence for early atherosclerosis. 
An ocular fundus examination was done to detect hypertensive retinopathy.
All the subjects had routine urine analysis (albumin, sugar and deposits) done. Fasting 
and 2 hour postprandial blood sugar, serum urea and creatinine were estimated. A 12 
lead electrocardiogram and chest X-ray were also taken.
All the patients were instructed to report with first early morning urine sample. Albumin 
in the urine is very stable at normal temperature, so urinary samples need not be frozen 
when sent to laboratory.
Microalbuminuria was detected by the immunoturbidometric assay.
 Procedure of the test
All  samples  were  tested  on  the  morning  of  the  visit  to  the  clinic. 
Microalbuminuria was detected by the immunoturbidometric assay. It is a fully 
automated  calibrated  system.  Urine Albumin  to  creatinine  ratio in  a 
random spot collection is calculated.
Albumin
Technology - fully automated immunoturbidometric assay.
Method - photometry 
Reference - adults range < 18mcg/ml
Creatinine
Technology - JAFFE Method - Rate Blanked and compensated 
Method - photometry 
Reference range:   a)Males - 39 - 259 mg/dl
b) Females - 28 - 217 mg/dl
Exclusion criteria
Diabetes mellitus
Microalbuminuria detected by dipstick (Trace–3+)
Obesity
Febrile patients
 Patients with UTI
Patients on ACE inhibitors
P
Ethical approval
Ethical committee clearance was obtained.
Consent
Informed consent was obtained from the subjects.
Statistical analysis
Computer analysis of data was done using a software epideomological 
information package developed by the Centers for Disease control and prevention-
Atlanta in collaboration with World Health Organization. Chi - square test is used for 
tests of significance.
Results and observation
R
TABLE NO 5.1: DISTRIBUTION OF VARIABLES IN THE STUDY GROUP
FREQUENCY PERCENTAGE CUMULATIVE
A. AGE 20-30 2 3.3 3.3
30-40 6 10.0 13.3
40-50 20 33.3 46.7
50-60 16 26.7 73.3
60-70 11 18.3 91.7
>70 5 8.3 100
B. SEX FEMALE 27 45 45
MALE 33 55 100
C. ECG CHANGES ABSENT 28 46.7 46.7
PRESENT 32 53.3 100
D. LVH ABSENT 33 55 55
PRESENT 27 45 100
E. CAD/LVF ABSENT 40 66.7 66.7
PRESENT 20 33.3 100
F. RETINOPATHY ABSENT 45 75 75
PRESENT 15 25 100
G. NEPHROPATHY ABSENT 53 88.3 88.3
PRESENT 7 11.7 100
H.  SECONDARY   HT 
CHANGES
ABSENT 54 90.0 90.0
PRESENT 6 10.0 100
I.MICRO-
ALBUMINURIA
ABSENT 22 36.7 36.7
PRESENT 38 63.3 63.3
J. SYSTOLIC HT (JNC 7) Stage I HT(140-159) 31 51.7 51.7
Stage II HT(≥160) 29 48.3 48.3
K. DIASTOLIC HT  (JNC 
7)
Stage I HT(90-99) 33 55.0 55.0
Stage II HT(≥100) 27 45.0 45.0
The age, sex, and target organ damage frequency and percentage distribution is depicted 
in the above table.
Age category
ATABLE NO. 5.2. CENTRAL TENDENCIES AND DISPERSION OF STUDY 
VARIABLES
↓VARIABLE MEAN MEDIAN SD
A. AGE 53.30 51.5 11.9
B. DURATION 41.37 36 24.8
C. SYSTOLIC BP 167.33 160 20.5
D. DIASTOLIC BP 104.6 100 11.3
E. PULSE PRESSURE 63.4 60 18.01
F.MEAN 
ARTERIAL PRESSURE 125.5 123.3 11.8
G. MICROALBUMINURIA 92.1 93.6 68.1
There  were  a  total  of  60  cases.  Out  of  60  cases  38(63%)  had 
microalbuminuria positive and 22(27%) tested   negative for microalbuminuria . 
In the study group 
Age distribution at the interval of 10 years, between 20 years and 70 years 
and above was included.  The mean age distribution in the study group is 53.30.The 
maximum number of cases 20 (33.33%) belongs to the 40-50 years category. The next 
large  number  of  cases  belongs  to  50-60years  category  around  16(26.67%) 
cases.11(18.33%) cases included in the 60-70 years ,6(10%) cases in 30-40 years and 
5(8.3%) cases in the >70 years and 2(3.3%) cases in 20-30 years category. The p value 
is 0.121 which is insignificant.
The sex distributions of the 60 cases, 33(55%) cases are males and 27(45%) 
cases are females.
Table  No.5.3:  RELATIONSHIP  BETWEEN  DURATION  OF  HT  AND 
MICROALBUMINURIA
MAU STATUS
ABSENT PRESENT
COUNT COUNT
COUNT
DURATION 
OF HT
1-59 M 19 67.9% 9 32.1% 28
60-119 M 3 9.7% 28 90.3% 31
>120 M 0 .0% 1 100.0% 1
TOTAL 22 36.7% 38 63.3% 60
In this study group, cases were categorized into three groups according to 
the duration of hypertension (i) 1-59 months, (ii) 60-119 months, (iii) >120 months.
Twenty eight cases presented in 1-59 months category. Out of 28 cases, 
9(32.1%)  tested  positive  for  microalbuminuria,  19(68%)  tested  negative  for 
microalbuminuria. 31  cases presented in 60-119 months category, 28(90%) cases tested 
positive for microalbuminuria, only 3(10%) cases tested negative for microalbuminuria. 
CORRELATION BETWEEN DURATION OF HT AND MICROALBUMINURIA
HAll cases in the category > 120 months tested positive for microalbuminuria 
(100%).
TABLE  NO  5.4:  CORRELATION  BETWEEN  DURATION  OF  HT  AND 
MICROALBUMINURIA
DURATION
OF HT
MICRO 
ALBUMINURIA
DURATION
OF.HT
PEARSON 
CORRELATION 1 .677(**)
SIG. (2-TAILED) .000
N 60 60
MICRO
ALBUMINURIA
PEARSON 
CORRELATION .677(**) 1
SIG. 
(2-TAILED) .000
N 60 60
CHI SQUARE TEST:   P<0.001* 
The p value is <0.001 and is statistically significant and duration of hypertension 
significantly correlates with microalbuminuria. 
s
This study  indicates  that  longer  the  duration of hypertension more  number of  cases 
are   microalbuminuric  and  is  statistically  significant (p<0.001).
TABLE NO.5.5: RELATIONSHIP BETWEEN SYSTOLIC BP AND 
MICROALBUMINURIA.
MICROALBUMINURIA TOTAL CHI 
SQUARE ABSENT PRESENT
SYSTOLIC BP STAGE I 
HT(140-159)
17 6 23
P<.001
 STAGE II HT(>=160) 5 32 37
TOTAL 22 38 60
The mean systolic blood pressure in the study group is 167 mm of Hg.
T
Among the study group 
23(38%) cases were in stage I Hypertension and 37(62%) cases were in stage II 
hypertension.
6/23(26%) cases in stage I hypertension were tested positive for 
microalbuminuria.17/23(74%) cases were tested negative for microalbuminuria.
 32/37(86%) cases in stage II hypertension tested positive for 
microalbuminuria.5/37(14%) cases tested negative for microalbuminuria. 
TABLE NO: 5.6: CORRELATION BETWEEN SYSTOLIC BP AND 
MICROALBUMINURIA
BP-SYS
MICRO 
ALBUMINURIA
BP-SYS PEARSON 
CORRELATION 1 .594(**)
SIG.(2-TAILED) P<001
N 60 60
MICRO 
ALBUMINURIA
PEARSON 
CORRELATION .594(**) 1
SIG. (2-TAILED) P<.001
N 60 60
The  p  value  is<0.001,  which  is  statistically  significant  and  correlates  with 
microalbuminuria.
m
TABLE NO: 5.7: RELATIONSHIP BETWEEN DIASTOLIC BP AND 
MICROALBUMINURIA
MICROALBUMINURIA TOTAL  CHI 
SQUARE ABSENT PRESENT
DIASTOLE 
BP JNC7
 
 
STAGEI 
HT(90-100) 7 6 13
P=0.197STAGEII 
HT(>100) 15 32 47
TOTAL 22 38 60
The mean diastolic blood pressure in the study group is 105 mmHg. Among 
the  study  group,  13  cases  were  in  stage  I  hypertension  and  47  cases  in  stage  II 
hypertension.6/13 in diastolic stage I hypertension tested positive for microalbuminuria.
32/47 cases tested positive for diastolic stage II hypertension. The p value is 
0.197, which is statistically insignificant, and does not correlate with severity.
0TABLE  NO:  5.8:  RELATIONSHIP  BETWEEN  PULSE  PRESSURE  AND 
MICROALBUMINURIA
MICROALBUMINURIA TOTAL CHI 
SQUAREABSENT PRESENT
PULSE 
PRESSUR
E
30-59 12 10 22
P=0.032*60-90 10 22 32
>90 0 6 6
TOTAL 22 38 60
The mean pulse pressure in study group is 63 mm of Hg.
The pulse pressure category is divided into three groups. In the pulse pressure 
category 30-59 mm of Hg, 22 cases were present and among 22 cases, 10.(45.5%) tested 
positive for microalbuminuria. In the pulse pressure category 60-90 mm of Hg, 32 cases 
were  tested  positive  and  among  32  cases,  22(68.8%)  cases  tested  positive  for 
microalbuminuria. In the pulse pressure category >90 mm of Hg, 6 cases were present 
and all (100%) cases tested positive for microalbuminuria.
a
TABLE  NO:  5.9:  CORRELATION  BETWEEN  PULSE  PRESSURE  AND 
MICROALBUMINURIA
PULSE PRESSURE MICRO 
ALBUMINURIA
PULSE PRESSURE PEARSON CORRELATION 1 .447(**)
SIG. (2-TAILED) P<0.001
N 60 60
MICRO 
ALBUMINURIA
PEARSON 
CORRELATION .447(**) 1
SIG. (2-TAILED) .000
N 60 60
TABLE NO. 5.10: RELATIONSHIP BETWEEN MICROALBUMINURIA AND 
ECG CHANGES
ECG CHANGE TOTAL
CHI SQUAREABSENT PRESENTMICROALBUMINURI
A
ABSENT 13 9 22 P=0.183
PRESENT 15 23 38
TOTAL 28 32 60
23/32(72%)  cases  which  presented  with  ECG  changes  tested  positive  for 
microalbuminuria. The p value is 0.183, which is statistically not significant.
LVH TOTAL CHI 
SQUAREABSENT PRESENT
MICROALBUMINURIA ABSENT 15 7 22
0.178PRESENT 18 20 38
TOTAL 33 27 60
 
 
TABLE.NO:5.11:  RELATIONSHIP  BETWEEN  MICROALBUMINURIA  AND 
LVH CHANGES
In the study group, 27 cases presented with LVH. Out of 27, 20(74%) cases 
tested positive for microalbuminuria. The p value is 0.178, which is not significant.
TABLE NO: 5.12: RELATIONSHIP BETWEEN MICROALBUMINURIA AND 
CAD/LVF
CAD/ LVF TOTAL CHI 
SQUAREABSENT PRESENT
MICROALBUMINURIA ABSENT 18 4 22 0.09
PRESENT 22 16 38
TOTAL 40 20 60
In this study 20 cases were presented with coronary artery diseases,  left 
ventricular failure. Out of 20 cases 16 tested positive for microalbuminuria. 
The p value is 0.09, which is less significant.
TTABLE  NO.5.13:  RELATIONSHIP  BETWEEN  MICROALBUMINURIA  AND 
RETINOPATHY
RETINOPATHY TOTAL CHI SQUAREABSENT PRESENT
MICROALBUMINURIA ABSENT 22 0 22
P<001**
PRESENT 23 15 38
TOTAL 45 15 60
In  this  study,15 cases  presented  with  retinopathy  all  cases  tested 
positive  for  microalbuminuria(100%).The  p  value  is  <0.001  and  is  statistically 
significant. 
In  this  study,  microalbuminuria  correlates  significantly  with 
retinopathy.
TABLE  5.14:  RELATIONSHIP  BETWEEN  MICROALBUMINURIA  AND 
NEPHROPATHY
NEPHROPATHY TOTAL CHI 
SQUAREABSENT PRESENT
MICROALBUMINURIA ABSENT 22 0 22
P<.033**
PRESENT 31 7 38
TOTAL
53 7
60
Out of 7 cases, all 7 cases tested positive for microalbuminuria (100%).The 
p value is 0.03, and is statistically significant.
TABLE  NO.5.15:  RELATIONSHIP  BETWEEN  MICROALBUMINURIA  AND 
SECONDARY HT
SECONDARY HT TOTAL CHI 
SQUAREABSENT PRESENT
MICROALBUMINURIA ABSENT 25 0 25
0.029**PRESENT 29 6 35
TOTAL 54 6
6In this study, 6 cases presented with secondary hypertension.2 cases were 
pheochromocytoma, 2 cases were renal artery stenosis and 2 cases of coarctation of 
aorta. All 6(100%) cases tested positive for microalbuminuria.
The p value is 0.029 and is statically significant. 
TABLE NO 5.16: RELATIONSHIP BETWEEN MICROALBUMINURIA AND CVA
CVA
TOTAL
CHI SQ
ABSENT PRESENT
MAU 
STATUS
ABSENT 20 2 22
P=0.229*PRESENT 29 9 38
TOTAL 49 11 60
In this study, 11 cases presented with cerebrovascular accident. Out of 11 cases of CVA, 
9(82%) cases tested positive for microalbuminuria. Only 2(18%) cases tested negative 
for microalbuminuria.
The P value is 0.229, which is less significant. 
TTABLE NO 5.16: RELATIONSHIP BETWEEN MICROALBUMINURIA AND TARGET ORGAN DAMAGE
TOD
TOTAL
CHI SQ
ABSENT PRESENT
MAU STATUS ABSENT 12 10 22 P=0.024*
PRESENT 9 29 38
TOTAL 21 39 60
In this study, 29(74%) out of 39 cases presented with target organ damage were tested 
positive for microalbuminuria. 
The p value is 0.024 and is correlated statistically significant.
Discussion and comparative analysis
D
DISCUSSION AND COMPARATIVE ANALYSIS
In  the  present  study, out  of  sixty  cases  of  hypertension  38  cases  had 
microalbuminuria. The prevalence of microalbuminuria in hypertension in this study 
shows 63.33%. This study has high prevalence of microalbuminuria. 
 In an Indian study conducted by kothiawale, Jagadeesh, Preethy, Verghesse, 
Solbannvara., KLE hospital Belgam the prevalence of microalbuminuria  was 48%. 
In another Indian study conducted by V.K. Sharma,T.N Dubey,R.K.Jain.,Gandhi 
hospital Bhopal, prevalence of  microalbuminuria  was 24%  and had a significant 
correlation with severity of hypertension.It showed that cases having less than 10 yrs 
duration of hypertension, only 32% had microalbuminuria whereas cases having more 
than 10 yrs duration of hypertension all cases (100%) had microalbuminuria.
This study shows that among  cases  having  less  than  5 yrs duration  of  hypertension 
9/28(32.1% ) cases  had  Microalbuminuria. Among cases between 5&10 yrs duration of 
hypertension 28/31(90.3%) cases had microalbuminuria. Among cases having more than 
10 yrs duration of hypertension all (100%) had microalbuminuria.
1
This study  indicates  that  longer  the  duration of hypertension more  number of  cases 
are   microalbuminuric  and  is  statistically  significant (p<0.001).
In the clinical epidemiology study conducted by John Forman and Naomi, showed 
increasing microalbuminuria even within normal range which is considered normal, is 
independently associated with an increased risk for development of hypertension.
          Likewise severity of hypertension had significant correlation with 
microalbuminuria, among 38 cases who presented with microalbuminuria.
Palatine p. et al in their study on 870 never treated hypertensives, found that family 
history of hypertension, smoking, alcohol, coffee intake and physical activity habits did 
not influence albumin excretion rate.
Convincing evidence has shown association of elevated urinary albumin execretion in 
hypertension with higher systolic blood pressure and pulse pressure through pressure 
dependant and non pressure dependant mechanisms, overweight, glucose intolerance, 
other phenotypes of metabolic syndrome smoking, genetically determined elevated renin 
angiotensin II levels and/or activity.
Furthermore, microalbuminuria consistently showed independent connection with 
cardiovascular morbidity and mortality. Besides, sharing 
adverse cardiovascular and metabolic risk pattern, it may be characterized by 
hyperfiltration possibly conducive to glomerular hypertension and eventually .renal 
insufficiency.
This study correlates  systolic  blood pressure, diastolic blood pressure , pulse pressure 
with microalbuminuria and is statistically very significant (p<0.001) with  systolic 
blood pressure and  pulse pressure .
 In Parving HH et.al shows a positive correlation with systolic and pulse pressure. In 
creosola g.et.al study shows a positive correlation of diastolic blood pressure with 
microalbuminuria. 
 This study shows 6/23(26.08%) cases in stage I HT and 32/37(86.48%) cases in 
stage II HT tested positive for microalbuminuria. 
The severity of hypertension significantly correlates with microalbuminuria (P<0.001). 
In an Indian study conducted by kothiawale, Jagadeesh, Preethy, Verghesse, 
Solbannvara., KLE hospital Belgam 30% cases in stage I HT and 70% cases  in stage II 
HT  tested  positive  for  microalbuminuria.
 This study indicates that higher the numbers of systolic blood pressure values 
more  number of cases are microalbuminuric.
m
 This study shows a significant correlation between target organ damage with 
microalbuminuria and it shows 29/39 of TOD (74.35%) cases tested positive with 
microalbuminuria.  
Among patients with target organ damage (T0D) 
15/15 (100%) cases of Retinopathy tested positive for microalbuminuria. 
7/7 (100%) cases of Nephropathy tested positive for microalbuminuria.
20/27 (74%) cases of LVH tested positive for microalbuminuria and 7(26%) cases tested 
negative for microalbuminuria.  
16/20 (80%) cases of CAD/LVF tested positive for microalbuminuria and 4 cases tested 
negative for microalbuminuria.
9/11 (82%) cases of CVA tested positive for microalbuminuria and only 2/11(18%) 
cases tested negative for microalbuminuria. 
           In Agarwal et al. study of 11,343 non diabetic hypertensives, those with 
microalbuminuria had a significantly prevalence of higher prevalence of 
microalbuminuria  (P<0.001) of coronary artery disease (31% vs 22%),left ventricular 
hypertrophy(24% Vs 14%), previous stroke (6% Vs 4%),peripheral vascular disease(7% 
Vs 5%).
In an Indian study conducted by kothiawale, Jagadeesh, Preethy, Verghesse, 
Solbannvara., KLE hospital Belgam microalbuminuria showed a 
positive correlation  with  Retinopathy (100%), Nephropathy (100%), and LVH (85%), 
and 16/20 cases of  CAD/LVF(65%),and 9/11  cases of CVA(85%).
This study included cases of secondary hypertension and all cases   (100%) tested 
positive for microalbuminuria.
CLINICAL IMPLICATION
The prevention of hypertension is the major focus of the most recent JNC report which 
emphasizes that the individuals with the systolic blood pressure of > 120mm of Hg or 
diastolic blood pressure > 80 mm of Hg are at risk of progessing to risk of overt 
hypertension. The size of prehypertension category is considered high. It would be 
useful for clinician to have a biochemical test that could aid in the identification of 
individuals, most likely to develop hypertension. URINE ALBUMIN CREATININE 
RATIO (UACR) is a candidate for such a marker and it is comparable to other markers 
such as C-reactive protein, assessed for prediction of cardiovascular events in healthy 
poplutations.
Large studies confirmed that very low degrees of urine albumin excretion below the 
conventional threshold for microalbuminuria (UACR of 30 mg/gm) as low as 1.7 to 3.8 
mg/gm for men and 3.4-7.5 mg/gm for women were associated with 71% increase in 
risk for developing hypertension.
r
Low grade albumin excretion has also been associated with risk of cardiovascular events 
in both diabetic and non-diabetic individuals. Many studies support to the notion that 
conventional microalbuminuria may be higher than the cut point at the substantial risk 
for adverse outcomes begins to be detectable.
In this study, microalbuminuria had a stronger association with target organ damage and 
therefore, screening for microalbuminuria in hypertensive patients is recommended as a 
cost effective biochemical tool in detecting future adverse outcomes, and thereby 
pharmacological and non pharmacological interventions can be made at the earliest.  
 In a recent study by Lazzara and Deen suggested, that states of glomerular 
hyperfiltration or increased activity of the renin angiotensin system of the kidney may 
provide a link between higher levels of albumin excretion and the development of 
hypertension.
European guidelines for Hypertension emphasize the importance of assessing the 
importance of target organ damage for cardiovascular risk stratification. Non invasive 
assessment of cardiac and peripheral arterial structures by ultrasonagraphy is of 
relatively high cost and hence not performed routinely, recommended in selected cases.
Optimizing the diagnostic approach to the detection of target organ damage 
is utmost importance for a rationale and cost effective allocation of economic resources.
Evaluation of microalbuminuria is recommended as a screening tool for 
target organ damage especially in low risk patients in Hypertension.
 Therefore Urinary screening for microalbuminuria atleast once in a year in 
every hypertensive patients improves the targeting of primary prevention and results in 
reduction in target organ damage.
Current challenges therefore should preclude the inclusion of microalbuminuria in the 
routine management of hypertensive patients.    
Heightened awareness of microalbuminuria as an early prognostic indicator of target 
organ damage risk, knowing when, how, and in whom to screen for it, and finally, 
knowing the strategies to manage it are therefore essential prerequisities in therapeutic 
decision making process.
Conclusion
CONCLUSION
In this study of 60 patients with hypertension, the prevalence of microalbuminuria was 
found to be high.
The presence of microalbuminuria in hypertension is statistically correlated with the 
duration of hypertension.
This study showed statistically significant correlation with systolic blood pressure and 
pulse pressure, but not with diastolic pressure.
This study showed statistically significant correlation with severity of hypertension 
(JNC 7 STAGING).
This study showed statistically significant correlation with target organ damage.
.Therefore urinary screening for microalbuminuria in patients with hypertension 
improves the targeting of primary prevention and should result in the reduction of target 
organ damage. 
 
PROFORMA
NAME: AGE: SEX:
ADDRESS: OCCUPATION:
DURATION OF HYPERTENSION: OP/IP NO. :
UNIT:
SYMPTOMS:
Head ache Polyuria Cold intolerance
Giddiness Oliguria Weight gain
Blurring of vision Puffiness of face Hoarseness of vision
Epistaxis Swelling of legs Centripetal obesity
Chest pain Anorexia Hirsuitism
Palpitation Easy fatiguability Amenorrhoea/Menorrhagia
Dyspnoea Altered bowel habits Episodes of weakness
Fever Hematuria UTI
U
PAST HISTORY DRUG INTAKE
DM OCP
Renal disorders Corticosteroids
Thyroid disorders
PERSONAL HISTORY
Smoking Alcoholism Drug abuse
FAMILY HISTORY
HT DM
ANTHROPOMETRY
Height (in cm): Weight (in kg): BMI:
GENERAL EXAMINATION
Fundus Xanthoma
Thyroid swelling Xanthelesma
Skin manifestations of thyroid disorders
Features of Cushing’s syndrome
F
PULSE
Rate Rhythm Volume Character
Radio femoral delay Peripheral pulses
BLOOD PRESSURE ( in mm hg)
R L                R L
Sitting posture                UL            LL
Lying posture  UL                       LL
SYSTEMIC EXAMINTION
CVS:
RS:
ABDOMEN:
CNS:
INVESTIGATIONS
Blood Glucose: Urea: Creatinine:
ECG: ECHO: Chest X Ray
C
URINE Albumin: Sugar: Deposits:
MICROALBUMINURIA
(Albumin creatinine Ratio)
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ABBREVIATION
ACE - Angiotiotensin converting enzyme
ARB - Angiotensin receptor blockade
AT 1 – Angiotensin I receptor
BP – Blood pressure
CAD – Coronary heart Disease
CVA-Cerebro Vascular Accident
ECG – Electrocardiogram
DM – Diabetes Mellitus
HT – Hypertension
JNC – Joint national committee
LVH – Left Ventricular Hypertrophy
MAU -microalbuminuria
PAD – peripheral arterial disease
P
RAS – Renin angiotensin system
TGF-β – transforming growth factor
TOD – Target organ damage
UTI – Urinary tract infection
UACR – Urinary albumin creatinine ratio
